MARKET

SLNO

SLNO

Soleno Therapeutics Inc
NASDAQ
87.20
-0.44
-0.50%
After Hours: 87.20 0 0.00% 16:32 07/18 EDT
OPEN
88.25
PREV CLOSE
87.64
HIGH
88.82
LOW
86.24
VOLUME
1.19M
TURNOVER
--
52 WEEK HIGH
90.32
52 WEEK LOW
41.50
MARKET CAP
4.52B
P/E (TTM)
-18.8875
1D
5D
1M
3M
1Y
5Y
1D
Soleno Therapeutics: Fairly Valued Despite M&A Expectations
Seeking Alpha · 3d ago
Soleno Therapeutics (SLNO) Receives a Buy from Oppenheimer
TipRanks · 5d ago
Weekly Report: what happened at SLNO last week (0707-0711)?
Weekly Report · 5d ago
Soleno Therapeutics Is Maintained at Outperform by Baird
Dow Jones · 07/11 12:18
Baird Maintains Outperform on Soleno Therapeutics, Raises Price Target to $121
Benzinga · 07/11 12:08
Soleno Therapeutics price target raised to $121 from $105 at Baird
TipRanks · 07/11 11:20
Soleno Therapeutics Announces Public Stock Offering
TipRanks · 07/11 10:29
SOLENO THERAPEUTICS INC <SLNO.O>: BAIRD RAISES TARGET PRICE TO $121 FROM $105
Reuters · 07/11 03:19
More
About SLNO
Soleno Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of rare diseases. The Company’s lead product candidate, diazoxide choline extended-release tablets (DCCR), is for the treatment of Prader-Willi syndrome (PWS) in individuals four years and older who have hyperphagia. DCCR contains diazoxide choline, a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. Its proposed mode of action, with targets in the brain, pancreas and fat tissue, has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food-seeking, decrease insulin and leptin resistance, and reduce body fat. The Company has Breakthrough Therapy and Fast-Track designations in the United States and Orphan Drug designations in the United States and European Union.

Webull offers Soleno Therapeutics Inc stock information, including NASDAQ: SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.